FY2022 Earnings Estimate for Nkarta, Inc. Issued By Oppenheimer (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTXGet Rating) – Analysts at Oppenheimer decreased their FY2022 earnings estimates for Nkarta in a research note issued on Thursday, November 10th. Oppenheimer analyst M. Biegler now anticipates that the company will post earnings per share of ($2.59) for the year, down from their prior forecast of ($2.31). Oppenheimer has a “Outperform” rating and a $36.00 price objective on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($2.64) per share. Oppenheimer also issued estimates for Nkarta’s Q4 2022 earnings at ($0.65) EPS, FY2023 earnings at ($2.89) EPS, FY2024 earnings at ($3.07) EPS, FY2025 earnings at ($2.94) EPS and FY2026 earnings at ($2.91) EPS.

A number of other analysts also recently weighed in on the stock. SVB Leerink started coverage on shares of Nkarta in a report on Monday, July 18th. They set an “outperform” rating and a $30.00 price target for the company. Canaccord Genuity Group started coverage on Nkarta in a research report on Monday, October 10th. They set a “buy” rating and a $25.00 target price for the company. Canaccord Genuity Group started coverage on Nkarta in a report on Monday, October 10th. They set a “buy” rating and a $25.00 price target for the company. Needham & Company LLC initiated coverage on Nkarta in a report on Thursday, July 28th. They set a “buy” rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Nkarta in a research note on Wednesday, September 21st. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $33.30.

Nkarta Stock Up 5.5 %

NASDAQ NKTX opened at $11.14 on Monday. The company has a market capitalization of $543.79 million, a P/E ratio of -4.17 and a beta of 0.13. Nkarta has a 12-month low of $7.55 and a 12-month high of $20.35. The firm has a 50-day moving average price of $12.98 and a two-hundred day moving average price of $13.80.

Nkarta (NASDAQ:NKTXGet Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11.

Hedge Funds Weigh In On Nkarta

A number of institutional investors have recently bought and sold shares of NKTX. Price T Rowe Associates Inc. MD raised its stake in Nkarta by 64.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,879,662 shares of the company’s stock worth $47,797,000 after buying an additional 1,520,473 shares in the last quarter. SR One Capital Management LP purchased a new stake in Nkarta in the second quarter worth about $16,427,000. State Street Corp grew its holdings in Nkarta by 392.0% in the second quarter. State Street Corp now owns 1,359,615 shares of the company’s stock worth $16,750,000 after purchasing an additional 1,083,297 shares during the period. FMR LLC grew its holdings in Nkarta by 523,829.2% in the second quarter. FMR LLC now owns 880,201 shares of the company’s stock worth $10,844,000 after purchasing an additional 880,033 shares during the period. Finally, Laurion Capital Management LP purchased a new stake in Nkarta in the second quarter worth about $10,669,000.

Insider Activity

In related news, CEO Paul J. Hastings sold 23,376 shares of the company’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total value of $304,589.28. Following the completion of the transaction, the chief executive officer now directly owns 250,959 shares in the company, valued at $3,269,995.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of the business’s stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total value of $304,589.28. Following the completion of the sale, the chief executive officer now directly owns 250,959 shares of the company’s stock, valued at $3,269,995.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paul J. Hastings sold 6,126 shares of the business’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $13.01, for a total transaction of $79,699.26. Following the completion of the sale, the chief executive officer now directly owns 274,335 shares of the company’s stock, valued at $3,569,098.35. The disclosure for this sale can be found here. Insiders sold 30,344 shares of company stock worth $396,093 in the last three months. Corporate insiders own 5.60% of the company’s stock.

About Nkarta

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Further Reading

Earnings History and Estimates for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.